Articles with public access mandates - Christopher B. FoxLearn more
Not available anywhere: 7
Monitoring the effects of component structure and source on formulation stability and adjuvant activity of oil-in-water emulsions
CB Fox, RC Anderson, TS Dutill, Y Goto, SG Reed, TS Vedvick
Colloids and Surfaces B: Biointerfaces 65 (1), 98-105, 2008
Mandates: US National Institutes of Health
Evaluation of the stability of a spray-dried tuberculosis vaccine candidate designed for dry powder respiratory delivery
M Gomez, J McCollum, H Wang, S Bachchhav, I Tetreau, A Gerhardt, ...
Vaccine 39 (35), 5025-5036, 2021
Mandates: US National Institutes of Health
Molecular design of squalene/squalane countertypes via the controlled oligomerization of isoprene and evaluation of vaccine adjuvant applications
K Adlington, J El Harfi, J Li, K Carmichael, JA Guderian, CB Fox, DJ Irvine
Biomacromolecules 17 (1), 165-172, 2016
Mandates: UK Engineering and Physical Sciences Research Council
Current status of Toll-like receptor 4 ligand vaccine adjuvants
CB Fox, D Carter, RM Kramer, AM Beckmann, SG Reed
Immunopotentiators in Modern Vaccines, 105-127, 2017
Mandates: Bill & Melinda Gates Foundation, US National Institutes of Health
Lyophilization of an Adjuvanted Mycobacterium tuberculosis Vaccine in a Single-Chamber Pharmaceutical Cartridge
L Barnes V, DM Fedor, S Williams, QM Dowling, MC Archer, S Cloutier, ...
AAPS PharmSciTech 18, 2077-2084, 2017
Mandates: Bill & Melinda Gates Foundation
Innovations in emulsion technology
CB Fox, D Carter, SL Baldwin, SG Reed
Future Medicine Ltd, 2012
Mandates: US National Institutes of Health
E-104 Design and Development of Adjuvants for HIV Vaccines
S Reed, D Carter, C Fox, R Kramer, T Vedvick
JAIDS Journal of Acquired Immune Deficiency Syndromes 67, 60, 2014
Mandates: US National Institutes of Health, Danish Council for Independent Research
Available somewhere: 87
Key roles of adjuvants in modern vaccines
SG Reed, MT Orr, CB Fox
Nature medicine 19 (12), 1597-1608, 2013
Mandates: US National Institutes of Health
Use of defined TLR ligands as adjuvants within human vaccines
MS Duthie, HP Windish, CB Fox, SG Reed
Immunological reviews 239 (1), 178-196, 2011
Mandates: US National Institutes of Health
Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant
RN Coler, S Bertholet, M Moutaftsi, JA Guderian, HP Windish, SL Baldwin, ...
PloS one 6 (1), e16333, 2011
Mandates: US National Institutes of Health
Optimizing the utilization of aluminum adjuvants in vaccines: you might just get what you want
H HogenEsch, DT O’Hagan, CB Fox
npj Vaccines 3 (1), 51, 2018
Mandates: Bill & Melinda Gates Foundation, US Department of Agriculture
Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses
KO Saunders, E Lee, R Parks, DR Martinez, D Li, H Chen, RJ Edwards, ...
Nature 594 (7864), 553-559, 2021
Mandates: US Department of Defense, US National Institutes of Health
A nanostructured lipid carrier for delivery of a replicating viral RNA provides single, low-dose protection against Zika
JH Erasmus, AP Khandhar, J Guderian, B Granger, J Archer, M Archer, ...
Molecular Therapy 26 (10), 2507-2522, 2018
Mandates: US National Institutes of Health
Working together: interactions between vaccine antigens and adjuvants
CB Fox, RM Kramer, L Barnes V, QM Dowling, TS Vedvick
Therapeutic advances in vaccines 1 (1), 7-20, 2013
Mandates: US National Institutes of Health
3M-052, a synthetic TLR-7/8 agonist, induces durable HIV-1 envelope–specific plasma cells and humoral immunity in nonhuman primates
SP Kasturi, MAU Rasheed, C Havenar-Daughton, M Pham, T Legere, ...
Science immunology 5 (48), eabb1025, 2020
Mandates: Bill & Melinda Gates Foundation, US National Institutes of Health
Adjuvant formulation structure and composition are critical for the development of an effective vaccine against tuberculosis
MT Orr, CB Fox, SL Baldwin, SJ Sivananthan, E Lucas, S Lin, T Phan, ...
Journal of Controlled Release 172 (1), 190-200, 2013
Mandates: US National Institutes of Health
Mimicry of an HIV broadly neutralizing antibody epitope with a synthetic glycopeptide
SM Alam, B Aussedat, Y Vohra, RR Meyerhoff, EM Cale, WE Walkowicz, ...
Science translational medicine 9 (381), eaai7521, 2017
Mandates: US National Institutes of Health
Adjuvants for Leishmania vaccines: from models to clinical application
VS Raman, MS Duthie, CB Fox, G Matlashewski, SG Reed
Frontiers in immunology 3, 144, 2012
Mandates: US National Institutes of Health, Canadian Institutes of Health Research
Squalene emulsion potentiates the adjuvant activity of the TLR4 agonist, GLA, via inflammatory caspases, IL‐18, and IFN‐γ
AL Desbien, SJ Reed, HR Bailor, ND Cauwelaert, JD Laurance, MT Orr, ...
European journal of immunology 45 (2), 407-417, 2015
Mandates: Bill & Melinda Gates Foundation
Immunomodulatory and physical effects of oil composition in vaccine adjuvant emulsions
CB Fox, SL Baldwin, MS Duthie, SG Reed, TS Vedvick
Vaccine 29 (51), 9563-9572, 2011
Mandates: US National Institutes of Health
Publication and funding information is determined automatically by a computer program